-
Mashup Score: 0Bevacizumab Biosimilar Demonstrated Similar Efficacy, Safety as Reference Product Among Patients With Metastatic Colorectal Cancer - 8 month(s) ago
The bevacizumab biosimilar, bevacizumab-awwb, was effective and well-tolerated in the first-line setting among patients with metastatic colorectal cancer.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Impact of BRCA1 and RAD15 Methylation on Maintenance Olaparib Plus Bevacizumab Efficacy in Ovarian Cancer - 9 month(s) ago
At the 2023 ASCO Annual Meeting, Helene Blons, PhD, PharmD, discusses results from an abstract addressing the impact of BRCA1 and RAD51 methylation on the efficacy of olaparib plus bevacizumab maintenance treatment, from the PAOLA-1/ENGOT-ov25 trial.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
At the 2023 @ASCO annual meeting, Helene Blons, PhD, PharmD, discussed results from the PAOLA-1/ENGOT-ov25 trial. Learn more here: https://t.co/EVbv6Q0JeW #medtwitter #onctwitter #olaparib #bevacizumab #ASCO23 https://t.co/pAXt4PgrzW
-
-
Mashup Score: 0FDA Approval of Trifluridine and Tipiracil With Bevacizumab for Patients With Previously Treated Metastatic Colorectal Cancer - 9 month(s) ago
On August 2, 2023, the FDA granted approval to trifluridine and tipiracil plus bevacizumab for the treatment of patients with previously treated metastatic colorectal cancer.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Exciting news! On August 2, 2023, the @US_FDA approved #trifluridine and #tipiracil with #bevacizumab for patients with mCRC. Read more here: https://t.co/Lrbkz9s1zs #onctwitter #medtwitter #colorectalcancer https://t.co/Ho9EXDnU7l
-
-
Mashup Score: 0A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors - 10 month(s) ago
This is the first study to evaluate the combination of bevacizumab, temsirolimus, and valproic acid in patients with advanced malignancies. This combination dem
Source: OUP AcademicCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In patients with advanced solid tumors who have been heavily pretreated, combination therapy with #bevacizumab, #temsirolimus, and valproic acid was feasible, but numerous adverse events were observed, which will require careful management. @BlessieNelson https://t.co/NiH6O3osfT https://t.co/DejCwTnR0V
-
-
Mashup Score: 0KEYNOTE-826 Data Confirm Survival Benefit of Pembrolizumab Addition in Cervical Cancer - 10 month(s) ago
In an interview with Targeted Oncology, Bradley J. Monk, MD, FACCOG, FACS, highlighted final results from the phase 3 KEYNOTE-826 trial of pembrolizumab plus chemotherapy vs chemotherapy plus placebo, with or without bevacizumab in persistent, recurrent, or metastatic cervical cancer.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Bradley J. Monk, MD, FACCOG, FACS, discussed the final results from the phase 3 KEYNOTE-826 trial evaluating pembrolizumab plus chemotherapy with or without #bevacizumab in persistent, recurrent, or metastatic cervical cancer. #gyncsm | @TheUSONetwork https://t.co/u4i4UFoJAC https://t.co/pj8wAC7Bgy
-
-
Mashup Score: 0
Additional findings from KEYNOTE-826 reveal no negative health-related quality-of-life impact when using pembrolizumab plus chemotherapy with or without bevacizumab.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Treatment with the FDA-approved combination of #pembrolizumab plus chemotherapy with or without #bevacizumab does not have a negative impact on HRQOL, according to new findings from KEYNOTE-826. #gyncsm https://t.co/Yw2GCd6mh7
-
-
Mashup Score: 0
According to Alice P. Chen, MD, the phase 2 study of atezolizumab alone or atezolizumab plus bevacizumab has a unique design.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
At @theNCI, #atezolizumab alone or in combination with #bevacizumab is being investigated for the treatment of patients with alveolar soft part #sarcoma. https://t.co/eYid3iCJDE
-
-
Mashup Score: 0
DKN-01, an anti-DKK1 antibody, is being evaluated with bevacizumab and chemotherapy for patients with advanced colorectal cancer in the phase 2 DeFianCe trial.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
DKN-01, an anti-DKK1 antibody, is being evaluated with #bevacizumab and #chemotherapy for patients with advanced #colorectalcancer in the phase 2 DeFianCe trial. #crcsm https://t.co/She3hYYTQ8
-
-
Mashup Score: 0Adding panitumumab vs. bevacizumab to chemotherapy extends OS in colorectal cancer subset - 1 year(s) ago
The addition of panitumumab vs. bevacizumab to standard first-line chemotherapy significantly extended OS for certain patients with RAS wild-type metastatic colorectal cancer, according to data published in JAMA. “Although this study showed significant improvement of survival in the overall population, subgroup analysis suggested no significant difference in overall survival between
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Adding Panitumumab vs. Bevacizumab to chemotherapy extends OS in colorectal cancer subset. https://t.co/DELjR5PfYd #Panitumumab #Bevacizumab #colorectalcancer #HemOnc #OncAlert #MedEd
-
-
Mashup Score: 0Switching From Aflibercept to Bevacizumab Results in Cost Savings Without Sacrificing Visual Acuity, Says Dr Jennifer Sun - 1 year(s) ago
The Protocol AC study analyzed visual acuity gains and cost if patients with diabetic macular edema started on bevacizumab, which costs less, and switched to aflibercept later, explained Jennifer K. Sun, MD, MPH, associate professor of ophthalmology and chief of the Center for Clinical Eye Research and Trials, Harvard Medical School; and chair, DRCR Retina Network.
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
In this @AJMC_Journal interview, Dr Jennifer Sun, a professor at @harvardmed, discusses why switching from #aflibercept to #bevacizumab can be cost-saving. #VisualAcuity. Watch here! https://t.co/HSHQb0S9c2 https://t.co/pWmbeE3lGl
-
As study authors stated, “the clinical effectiveness and tolerability data were as expected and consistent with previously published findings from real-world studies.” Learn more: https://t.co/uvytYKo2mx #medtwitter #onctwitter #bevacizumab #biosimilars https://t.co/QJmFagJC4T